TOPLINE: In patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (ERBB2)–negative metastatic breast cancer who progressed following endocrine plus cyclin-dependent kinase 4 and […]

TOPLINE: European adolescents and young adults (AYAs) aged 15-39 years had lower 5-year relative survival (RS) rates than children for most types of leukaemia and lymphoma, […]

TOPLINE: Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS) […]

TOPLINE: One in 6 patients in phase 2 cancer trials received treatments that were eventually approved by the US Food and Drug Administration (FDA), a new […]

TOPLINE: Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which […]

TOPLINE: Breast and colorectal cancer screening rates in 2023 surpassed pre-pandemic levels with increases of 7% and 12%, respectively, while cervical cancer screening remained 14% below […]

TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with the prevalence of all-grade cytokine release syndrome (CRS) being 48% […]

TOPLINE: Real-world treatment patterns and outcomes among older patients with follicular lymphoma show significant heterogeneity, with 13,423 Medicare beneficiaries aged ≥ 65 years followed through 2019. […]